Stifel Financial is a top pick for long-term growth with solid Q424 results, a 10% dividend hike & solid wealth management ...

Stifel analyst Paul Matteis lowered the firm’s price target on Biogen (BIIB) to $144 from $175 and keeps a Hold rating on the shares. The ...

Proprietary Insights – Stifel Discover delivers exclusive analysis and commentary from Stifel’s Chief Investment Officer, Chief Economist, Chief Washington Policy Strategist, equity research analysts, ...

MoneyLion operates a “content-as-a-service platform” called mFeed, and Stifel Discover is expected to deliver personalized ...

Stifel analysts maintained a Buy rating and a $10.00 price target for Alto Neuroscience (NYSE: ANRO), suggesting a positive outlook for the company's stock. Currently trading at $3.15 and near its ...

Stifel analysts maintained their Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA), currently trading at $5.24, with a steady price target of $21.00. According to InvestingPro data, analyst targets ...

We recently compiled a list of the 10 AI News Updates on Wall Street’s Radar. In this article, we are going to take a look at ...

With deal activity expected to continue this year, deal advisors and analysts weigh in on how regulatory changes and private equity investment could play out in the sector.

Tesla (NASDAQ:TSLA – Get Free Report) had its price objective cut by research analysts at Stifel Nicolaus from $492.00 to ...

In the eyes of Tesla shareholders, Elon Musk hardly needed another distraction. OpenAI could turn out to be a costly one.

We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...

After reaching a net worth of more than $486 billion in December, Elon Musk’s wealth has sunk below $400 billion for the ...